Vieri Scotti

Florence, 50134, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 125 publications

Multidisciplinary Decision-Making and Integrated Strategies in Stage III Non-Small Cell Lung Cancer: Exploring Clinical Reasoning in Therapeutic Choices.

Multidisciplinary Decision-Making and Integrated Strategies in Stage III Non-Small Cell Lung Cancer: Exploring Clinical Reasoning in Therapeutic Choices.

Journal: Journal of clinical medicine

Published: March 10, 2026

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

EGFR-mutant NSCLC progressing on first-line osimertinib: rebiopsy in real-world and impact of second-line therapies (the 'Rebiopsy on osi' Study).

Journal: The oncologist

Published: February 11, 2026

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Amivantamab in advanced non-small cell lung cancer with epidermal growth factor receptor exon 20 insertion mutations: Real-world data from the Italian ATLAS Registry.

Journal: Cancer

Published: December 16, 2025

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Adjuvant atezolizumab in surgically resected NSCLC patients with PD-L1 expression ≥ 50%: real-world data from the Italian ATLAS registry.

Journal: The oncologist

Published: September 19, 2025

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Advanced-stage ALK-positive non-small-cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: September 16, 2025

Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.

Retrospective evaluation of the "neutrophil-lymphocyte ratio" (NLR) in patients affected by locally advanced unresectable stage III NSCLC treated with Durvalumab within the Italian expanded access program (EAP): results of the neutrality trial.

Journal: Cancer treatment and research communications

Published: July 22, 2025

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.

Braf-mutant metastatic non-small-cell lung cancer: Real world data from the Italian biomarker atlas database.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 02, 2025

Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial).

Locally advanced NSCLC: overview of real-world pattern of recurrence in durvalumab era (LEOPARD trial).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: May 23, 2025

Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study.

Correlation between treatments and outcomes of patients with EGFR-mutated non-small-cell lung cancer that transitioned into small-cell lung cancer: an international retrospective study.

Journal: ESMO open

Published: March 05, 2025

A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020).

A prospective study on clinicians' attitudes and survival outcomes for patients with advanced NSCLC and poor performance status in the immunotherapy era: PICASO (GOIRC-04-2020).

Journal: Lung cancer (Amsterdam, Netherlands)

Published: February 14, 2025

MPUS is a big step forward for small organs.

MPUS is a big step forward for small organs.

Journal: Ultraschall in der Medizin (Stuttgart, Germany : 1980)

Published: February 05, 2025

Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group.

Navigating chemotherapy and immunotherapy in early-stage lung cancer. A critical review and statements from INTERACTION group.

Journal: Critical reviews in oncology/hematology

Published: December 07, 2024

Showing 1-12 of 125

Last Updated: 09/26/2026